Extended Data Fig. 2: Combined inhibition of PARP and ALK results in accumulation of DNA damage. | Nature Cancer

Extended Data Fig. 2: Combined inhibition of PARP and ALK results in accumulation of DNA damage.

From: Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex

Extended Data Fig. 2

Representative images of γH2AX with EdU/DAPI staining in PARP inhibitor (PARPi)-resistant ovarian and triple-negative breast cancer (TNBC) cells treated with 0.25 μM PARPi (talazoparib) or 0.5 μM ALK inhibitor (ALKi; lorlatinib), either alone or in combination, for 48 hours. Insets, 3.3× magnification. Bar, 20 µm. Data are representative of N = 3 independent experiments with similar results.

Back to article page